C. Zarate

Publications366
h-index80
Citations24,738
Highly Influential Citations1,136
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Manji
  • 361 Publications • 36,062 Citations
  • W. Drevets
  • 367 Publications • 47,351 Citations
  • R. Machado-Vieira
  • 208 Publications • 9,301 Citations
  • D. Luckenbaugh
  • 159 Publications • 15,427 Citations
  • Publications
  • Influence
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
CONTEXT Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of… Expand
  • 2,404
  • 139
  • PDF
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
BACKGROUND Ketamine exerts a robust, rapid, and relatively sustained antidepressant effect in patients with major depression. Understanding the mechanisms underlying the intriguing effects of… Expand
  • 888
  • 89
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Major depressive disorder affects around 16 per cent of the world population at some point in their lives. Despite the availability of numerous monoaminergic-based antidepressants, most patients… Expand
  • 752
  • 80
  • PDF
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
CONTEXT Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or… Expand
  • 725
  • 53
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and… Expand
  • 716
  • 51
  • PDF
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
BACKGROUND Currently, no pharmacological treatments for bipolar depression exist that exert rapid (within hours) antidepressant or antisuicidal effects. We previously reported that intravenous… Expand
  • 519
  • 27
  • PDF
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
OBJECTIVE Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an… Expand
  • 415
  • 23
Ketamine for Depression: Where Do We Go from Here?
Since publication of the first randomized controlled trial describing rapid antidepressant effects of ketamine, several reports have confirmed the potential utility of this dissociative anesthetic… Expand
  • 307
  • 21
  • PDF
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence.
OBJECTIVE Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset… Expand
  • 397
  • 19
  • PDF
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study
OBJECTIVE Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex. METHOD… Expand
  • 191
  • 18
  • PDF
...
1
2
3
4
5
...